3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
3
Thoracic
2
Tumor-Agnostic
1
Sarcoma
1
Other neoplasm
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Breast
1
Conditions
Thyroid Cancer, Papillary
1
Lymphatic Metastasis
1
Interventions
Cisplatin
619
pembrolizumab
323
Radiotherapy
319
Cetuximab
274
Docetaxel
220
Radiotherapy, Intensity-Modulated
210
Carboplatin
197
Fluorouracil
196
Paclitaxel
159
Nivolumab
138
Gemcitabine
124
Magnetic Resonance Spectroscopy
94
Radiation
85
Drug Therapy
77
Capecitabine
76
toripalimab
74
Surgical Procedures, Operative
62
durvalumab
60
Biopsy
52
Cyclophosphamide
48
Chemoradiotherapy
47
camrelizumab
46
Specimen Handling
46
Erlotinib Hydrochloride
46
Radiosurgery
45
130-nm albumin-bound paclitaxel
43
tislelizumab
42
Standard of Care
42
Platinum
41
Bevacizumab
40
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Spectrum Analysis
×
Head & Neck
×
Clear all
NCT03470259
2024-04-16
TARGET
University Medical Center Groningen
Phase 1
Completed
19 enrolled